("NetScientific" or the "Company" or the "Group")
Glycotest Strengthens Intellectual Property Portfolio with Japanese Patent Grant
Japanese patent joins five other patents to add significant protection to core technology
London, UK - 12 September 2016 - NetScientific plc ("NetScientific", AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that one of its portfolio companies, Glycotest, has been granted a Japanese patent for its core technology for early detection of life threatening liver disease.
Glycotest now holds a total of six patents in Australia, the US and Japan, covering the use of over 50 unique glycoprotein biomarkers for the diagnosis of liver cancers and other liver diseases.
Commenting on the news, François R. Martelet, Chief Executive Officer of NetScientific and Chairman of Glycotest said: "We are delighted that the Japanese patent can now be added to Glycotest's rising number of patents which add to the breadth of the IP for its liver disease diagnostic platform. These granted patents and additional pending applications put Glycotest in a strong position to further protect its proprietary technology as it continues to grow."
The full text of the announcement issued by Glycotest on 12 September 2016 is as follows:
Glycotest Intellectual Property Portfolio Strengthened by Grant of Japanese Patent
New York, NY-September 12, 2016-Glycotest Inc., announced today that a Japanese patent has been granted that provides important protection of the Company's core technology for early detection of life threatening liver disease.
Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver cancers and fibrosis-cirrhosis. The Company's mission is to reduce mortality and increase survival for the growing population at risk from serious liver diseases. Glycotest employs unique non-invasive blood tests based on proprietary serum biomarkers, biomarker panels and assay technology that exploit novel sugar-based disease signal chemistry.
The Japanese patent announced today joins five other patents previously granted in the United States and Australia which have been licensed exclusively and on a worldwide basis to Glycotest by Drexel University College of Medicine and the Blumberg Institute of the Hepatitis B Foundation, both in the Philadelphia area. These patents cover the use of over 50 unique glycoprotein biomarkers for the diagnosis of liver cancers and other liver diseases. In addition, the Company soon expects to announce positive developments in the patent protection of the proprietary assay technology required to measure these novel biomarkers. Together these granted patents and the additional pending applications protect Glycotest's proprietary liver disease diagnostic platform.
Commenting on these developments, Glycotest's Chief Executive Officer Lawrence Cohen said, "The Glycotest patent portfolio is becoming substantial and we expect more good news in the coming year regarding our intellectual property position. Our IP portfolio along with the outstanding clinical results of our HCC Panel achieved to date are forming the base of what we expect to be a very strong company in liver disease diagnostics."
- Ends -
For more information, please contact:
François R. Martelet, M.D., CEO
Ian Postlethwaite, CFO
Tel: +44 (0)20 3514 1800
Stifel Nicolaus Europe Limited (NOMAD and broker) Jonathan Senior / David Arch / Ben Maddison
Tel: +44 (0) 20 7710 7600
Consilium Strategic Communications
Mary-Jane Elliott / Chris Gardner / Jessica Hodgson / Chris Welsh / Laura Thornton
Tel: +44 (0)20 3709 5700
NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net
About Glycotest, Inc.
Glycotest is a private liver disease diagnostics company commercializing novel clinical laboratory testing services for patients at risk for liver cancers and fibrosis-cirrhosis. The Company was founded in 2012 on proprietary technology that originated at the Philadelphia area institutions Baruch S. Blumberg Institute and Drexel University College of Medicine. Learn more at www.glycotest.com.
This information is provided by RNS